We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Medtronic (MDT - Free Report) closed at $99.36 in the latest trading session, marking a +2.92% move from the prior day. This move outpaced the S&P 500's daily loss of 0.51%. Elsewhere, the Dow saw an upswing of 0.41%, while the tech-heavy Nasdaq depreciated by 1.07%.
Shares of the medical device company witnessed a gain of 11.76% over the previous month, beating the performance of the Medical sector with its gain of 8.21%, and the S&P 500's loss of 0.87%.
Investors will be eagerly watching for the performance of Medtronic in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.34, signifying a 1.47% drop compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $9.47 billion, showing a 5.66% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $5.98 per share and revenue of $38.97 billion, which would represent changes of +8.14% and +7.16%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Medtronic. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.04% decrease. Currently, Medtronic is carrying a Zacks Rank of #3 (Hold).
In the context of valuation, Medtronic is at present trading with a Forward P/E ratio of 16.15. This represents a discount compared to its industry average Forward P/E of 19.62.
It's also important to note that MDT currently trades at a PEG ratio of 2.26. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products was holding an average PEG ratio of 1.99 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 167, this industry ranks in the bottom 33% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Medtronic (MDT) Ascends While Market Falls: Some Facts to Note
Medtronic (MDT - Free Report) closed at $99.36 in the latest trading session, marking a +2.92% move from the prior day. This move outpaced the S&P 500's daily loss of 0.51%. Elsewhere, the Dow saw an upswing of 0.41%, while the tech-heavy Nasdaq depreciated by 1.07%.
Shares of the medical device company witnessed a gain of 11.76% over the previous month, beating the performance of the Medical sector with its gain of 8.21%, and the S&P 500's loss of 0.87%.
Investors will be eagerly watching for the performance of Medtronic in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.34, signifying a 1.47% drop compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $9.47 billion, showing a 5.66% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $5.98 per share and revenue of $38.97 billion, which would represent changes of +8.14% and +7.16%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Medtronic. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.04% decrease. Currently, Medtronic is carrying a Zacks Rank of #3 (Hold).
In the context of valuation, Medtronic is at present trading with a Forward P/E ratio of 16.15. This represents a discount compared to its industry average Forward P/E of 19.62.
It's also important to note that MDT currently trades at a PEG ratio of 2.26. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products was holding an average PEG ratio of 1.99 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 167, this industry ranks in the bottom 33% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.